- Open Access
MicroRNA-1908 functions as a glioblastoma oncogene by suppressing PTEN tumor suppressor pathway
- Xuewei Xia†1,
- Yong Li†4,
- Wenbo Wang1,
- Fang Tang5,
- Jie Tan4,
- Liyuan Sun4,
- Qinghua Li4,
- Li Sun4,
- Bo Tang2, 3Email author and
- Songqing He2, 3Email author
© Xia et al. 2015
- Received: 28 January 2015
- Accepted: 30 July 2015
- Published: 12 August 2015
We aimed to investigate whether miRNA-1908 is an oncogene in human glioblastoma and find the possible mechanism of miR-1908.
We investigated the growth potentials of miRNA-1908-overexpressing SW-1783 cells in vitro and in vivo. In order to identify the target molecule of miRNA-1908, a luciferase reporter assay was performed, and the corresponding downstream signaling pathway was examined using immunohistochemistry of human glioblastoma tissues. We also investigated the miRNA-1908 expression in 34 patients according to the postoperative risk of recurrence.
The overexpression of miRNA-1908 significantly promoted anchorage-independent growth in vitro and significantly increased the tumor forming potential in vivo. MiRNA-1908 significantly suppressed the luciferase activity of mRNA combined with the PTEN 3’-UTR. Furthermore, the expression levels of miRNA-1908 were significantly increased in the patients with a high risk of recurrence compared to that observed in the low-risk patients, and this higher expression correlated with a poor survival.
miRNA-1908 functions as an oncogene in glioblastoma by repressing the PTEN pathway. MiR-1908 is a potential new molecular marker for predicting the risk of recurrence and prognosis of glioblastoma.
- Glioblastoma Cell
- Colony Formation Assay
- PTEN Expression
- Glioblastoma Patient
- PTEN mRNA
Glioblastomas, the prognosis of which is highly dependent on the histological grade, are the most common malignancies of the central nervous system in humans. New molecular targets and treatment strategies are urgently needed to combat this disease. MicroRNAs (miRNAs) are small, endogenous noncoding RNAs composed of 18–23 nucleotides (nt) that post-transcriptionally regulate gene expression by targeting the 3’-untranslated regions of mRNAs [1–3]. Many miRNAs are proto-oncogenes or tumor suppressors [4–6], and their functions have been extensively studied in various cancer types, including glioblastoma [7–10]. Recent studies using genome-wide approaches have revealed that miRNAs, such as miR-7 , miR-128 , and miR-21 , are globally dysregulated in glioblastoma. Of note, there are some microRNAs differently expressed in adult glioblastomas and paediatric glioblastoma . Our aim was to investigate the role and mechanism of microRNAs in glioblastomas that could contribute to the diagnosis and prognostic evaluation of glioblastoma patients. MiR-1908 is a novel microRNA that is highly expressed in human adipocytes . But the potential role of miR-1908 in the carcinogenesis and tumor development of glioblastoma is unknown.
Indeed, mounting evidence has shown that the poor prognosis of patients with glioblastoma and therapeutic failure are associated with a number of abnormally activated signaling pathways, among which phosphoinositide 3-kinase (PI3K)/AKT signaling represents one of the most important regulatory pathways for the malignancy [16, 17]. Notably, aberrant Akt activation is a poor prognostic factor for glioblastoma of all stages and contributes to resistance to first-generation single-agent targeting therapy such as gefitinib, a tyrosine kinase inhibitor clinically used for patients with glioblastoma with EGFR over-activation [18, 19]. Biologically, activated AKT confers glioblastoma cells resistant to chemotherapy and radiation and promotes cancer cell survival, and in contrast, chemically synthetic compounds inhibiting AKT activation induce apoptosis of glioblastoma cells in vitro as well as in vivo . Moreover, AKT signaling contributes to oncogenesis through activating multiple downstream effector molecules. Of note, activated AKT phosphorylates tumor suppressor FOXO3a and impairs the transcription of its target genes related to cell growth arrest such as p21, inactivation of which has also been implicated in the promotion of tumor angiogenesis [21, 22]. In addition, mTOR, another substrate subjected to phosphorylation by AKT, enhances phosphorylation of S6K1 and 4E-BP1  and plays crucial roles in the regulation of ribosomal protein synthesis, for example, production of cyclin D1 and VEGF-A at both transcriptional and translational levels [24, 25]. It has been found that mediated by the above molecular mechanisms, both AKT/FOXO3a and AKT/mTOR pathways underlie lung cancer development and progression [26, 27]. Thus, inhibitors targeting these pathways might represent potentially applicable therapeutic agents against glioblastoma.
In the current study, we identify that miR-1908 is highly expressed in multiple subtypes of glioblastoma tissues and causes simultaneous downregulation of PTEN, leading to activation of both AKT/FOXO3a and AKT/mTOR pathways, consequently leading to accelerated proliferation and enhanced angiogenesis in glioblastoma.
Aberrant expression of miR-1908 in human glioblastoma cells was correlated with poor prognosis
Clinicopathological features of 47 patients with gliomas
NO. of patients
Mean age (years)
Gross total resection
Radiotherapy and chemotherapy
To further evaluate whether miR-1908 is related with prognosis of glioblastoma patients, we carried out bioinformatics analysis. In survival analysis of glioblastoma patients, we found that patients with higher miR-1908 expression levels had poorer disease free survival (DFS) than those with lower miR-1908 expression levels (Fig. 1e) which suggested that miR-1908 significantly affected prognosis of glioblastoma patients. Altogether, these data demonstrate that miR-1908 is upregulated in glioblastoma and that high miR-1908 expression predicts poor patient survival.
The effects of miR-1908 on proliferation of glioblastoma
MiR-1908 promotes invasion and sphere formation in glioblastoma cells
PTEN is a potential target of miR-1908, and PTEN levels are inversely correlated with miR-1908 levels in glioblastoma tissues
Both AKT/FOXO3a and AKT/mTOR signaling contribute to miR-1908-mediated malignant phenotype of glioblastoma cells
Repression of PTEN in glioblastoma cells was essential for miR-1908-induced proliferation
Recently, miRNAs have been shown to be important in maintenance of normal cellular function, and the dysregulation of miRNAs expression can result in cancer initiation and tumor progression [28–30]. MiR-1908 is a new member of the microRNA family. In this study, we investigated the expression, function, and mechanism of miR-1908 in glioblastoma. We found that miR-1908 is a risk factor in glioblastoma where it acts as an oncogene by regulating PTEN expression. In glioblastoma cells, overexpression of miR-1908 robustly promotes cell proliferation and invasion in vitro. In contrast, inhibition of endogenous miR-1908 remarkably abrogates the proliferation and invasion of glioblastoma cells. At the molecular level, both the AKT/FOXO3a and AKT/mTOR pathways contribute to miR-1908–mediated malignant phenotype of glioblastoma cells, likely mediated by suppressing PTEN expression. Of note, the close correlation between high miR-1908 expression and low expression of PTEN, as well as with the malignant properties of glioblastoma tumors, were also confirmed in planted tumors and in clinical glioblastoma samples, suggesting a possible role of miR-1908 in the development and progression of glioblastoma.
Each miRNA has the potential to target hundreds of genes that harbor target sequence in their 3’-UTR complementary to the seed region of the miRNA . PTEN is one of the most frequently mutated tumor suppressors in human cancer including brain tumors [31, 32]. PTEN loss was considered to be one of three oncogenic factors in glioblastomas . PTEN also suppresses migration; genetic deletion of the Pten tumor suppressor gene promotes cell motility , and PTEN reconstitution or overexpression inhibits cell motility in a variety of cell types . Mechanistically, PTEN reduces cell motility through a variety of pathways, and P13K/AKT is one important target of PTEN . In this study, overexpression of miR-1908 significantly decreased PTEN in glioblastoma cells to inhibit phosphorylated P13K and AKT, resulting in increase in proliferation, migration and invasion [37–39]. PTEN overexpression could restrain the increase in proliferation, migration and invasion in miR-1908-overexpresison glioblastoma cells.
Clinical studies have revealed that PTEN mutation in glioblastoma has no correlation with survival . Nevertheless, in anaplastic oligodendroglioblastomas and astrocytomas there was a positive correlation between PTEN alterations and poor prognosis [40, 41]. Furthermore, elevated AKT activity has been associated with poor prognosis . Paediatric patients harbouring PTEN mutation in tumours have poorer prognosis . Thorarinsdottir et al. reported that deficient PTEN expression was associated with worse overall survival in childhood high grade glioblastomas . Our findings could provide new guidance for glioblastoma treatment and improve prognoses in the future.
Clinical specimens and cell culture
A total of 47 giloma specimens and five normal brain samples frozen in liquid nitrogen were obtained from Affiliated Hospital of Guilin Medical University. No patients had received any anti-tumor treatments before biopsy. The human glioblastoma cell lines (A127, SW1783, U87, U373, LN-229, SW1088, Hs683, HFU251, SNB19, T98G, 1228 and 802) were cultured in RPMI-1640 (Invitrogen) supplemented with 10 % FBS (Gibco) and 1 % streptomycin/penicillin at 37 °C with 5 % CO2.
RNA extraction, reverse transcription, and real-time RT-PCR
Total RNA was extracted from freshly-frozen samples or cells with TRIzol reagent (Invitrogen). Total RNA was reverse-transcribed with First Strand cDNA Synthesis Kit (Invitrogen). Real time PCR reactions were conducted using Platinum SYBR Green qPCR SuperMix-UDG reagents (Invitrogen) on the PRISM 7900HT system (Applied Biosystems). All reactions were done in triplicate and reactions without reverse transcriptase were used as negative controls. The U6 or GAPDH were used as the endogenous controls and the 2-ΔΔCT equation was used to calculate the relative expression levels.
Oligonucleotide transfection and generation of stably transfected cell lines
Cells were seeded into 6-well plates, transfected with miR-1908 mimics or miR controls (50 nM, GenePharma) using Lipofactamine™ RNAiMAX (Invitrogen) and transfected with siMIF (100 nM, Invitrogen) or siRNA controls using Lipofactamine 2000 reagent (Invitrogen), and then harvested for assays 48 h later. The lentiviral plasmid pEZX-MR03 (GeneCopoeia) expressing 1908 (Cat, HmiR0274-MR03) or scrambled miRNA (Cat, CmiR0001-MR03) and Lenti-Pac HIV Expression Packaging mix (GeneCopoeia) were cotransfected into glioblastoma cells using EndoFectin Lenti transfection reagent (GeneCopoeia). After transfection for 48 h, lentiviral particles were harvested and then transduced into the glioblastoma cells, and the stably transfected cells were selected using puromycin and validated by real time Western blot.
MTT assay and colony formation assay
Glioblastoma cells were seeded at 1500 cells per well in 96-well plates after transfection. MTT assay was performed to test cell viability at 1, 2, 3, and 4 days, and the absorbance was measured at 490 nm with a spectrophotometric plate reader. For colony formation assay, cells were plated at 500 cells per well in six-well plates after transfection, and cultured for 14 days. Colonies were fixed with methanol, stained with 0.5 % crystal violet, and counted under the inverted microscope.
Western blot analysis
Western blot analysis was conducted using anti-phospho-AKT (ser473), anti-AKT, anti-FOXO3a, anti-phospho-S6K1 (Thr389), anti-S6K1 and anti-4E-BP1(Epitomics), anti-phospho-FOXO3a (ser253), and phospho-4E-BP1 (Ser65; Cell Signaling Technology), anti-p21, anti-cyclinD1 and anti-PTEN (BD PharMingen) antibodies.
Cell migration and invasion assays
The effects of miR-1908 or PTEN expression on cell migration and invasion were assessed using the wound-healing and Transwell assays as previously described .
In vivo tumor growth model
Male BALB/c nude mice aged 4 to 6 weeks were purchased from the Hunan Slac Jingda Laboratory Animal Co., Ltd (Changsha, China). For tumor growth assay, SUNE-1 cells stably overexpression miR-451 or scramble miRNA were resuspended in PBS and 1 × 106 cells (200 μl) were subcutaneously injected in the dorsal flank of nude mice. Tumor size was measured every 3 days and tumor volumes were calculated with the following formula: volume = (L × W2)/2, in which L meant the longest diameter and W meant the shortest diameter. Four weeks later, mice were sacrificed, and tumors were dissected and weighted. Animal handling and research protocols were approved by the Animal Care and Use Ethnic Committee.
After 19 days, mice were anesthetized and sacrificed, and tumors were removed, photographed, weighed, and sectioned (5 mm in thickness), followed by immunostaining. Following deparaffinization, sections were immunohistochemically analyzed using antibodies for miR-1908, Ki67, p-Akt, p-P13K, p-S6K1, and p-4E-BP1, respectively, and subsequently were pathologically confirmed for the tumor phenotype and specific immunostaining. The positive cells were counted and analyzed.
Luciferase reporter assay
The 3’-UTR (untranslated region) sequence of PTEN was predicted to interact with miR-1908 or a mutated sequence within the predicted target sites was synthesized and inserted into the XbaI and FseI sites of the pGL3 control luciferase reporter vector (Promega, Madison, WI). The luciferase reporter assay was performed as previously described .
MiR-1908 expression is frequently up-regulated in glioblastoma. Overexpression of miR-1908 promotes the malignant phenotype of glioblastoma cells by promoting cell proliferation, migration and invasion through silencing PTEN expression. These findings indicate that miR-1908 plays an important role as a tumor promotor in glioblastoma development.
This research was supported in part by The National Natural Science Foundation of China (No. 81060094, No. 81360367, No. 81160066 and No. 30870719); Scientific Research Foundation for Returned Scholars, Ministry of Education of China (jyb2010-01); Major Project of Science Research of Guangxi Universities (2013ZD046); The Natural Science Foundation of Guangxi (2014GXNSFBA118162), Special Project of Traditional Chinese Medicine of Guangxi Health Department (GZPT13-45), Guangxi Distinguished Experts Special Fund, Project supported by the Guangxi culture of new century academic and technical leader of special funds.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.View ArticlePubMedGoogle Scholar
- He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5:522–31.View ArticlePubMedGoogle Scholar
- Zamore PD, Haley B. Ribo-gnome: the big world of small RNAs. Science. 2005;309:1519–24.View ArticlePubMedGoogle Scholar
- Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004;101:2999–3004.PubMed CentralView ArticlePubMedGoogle Scholar
- Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435:834–8.View ArticlePubMedGoogle Scholar
- Garzon R, Fabbri M, Cimmino A, Calin GA, Croce CM. MicroRNA expression and function in cancer. Trends Mol Med. 2006;12:580–7.View ArticlePubMedGoogle Scholar
- Chou YT, Lin HH, Lien YC, Wang YH, Hong CF, Kao YR, et al. EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF. Cancer Res. 2010;70:8822–31.View ArticlePubMedGoogle Scholar
- Kong W, He L, Coppola M, Guo J, Esposito NN, Coppola D, et al. MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem. 2010;285:17869–79.PubMed CentralView ArticlePubMedGoogle Scholar
- Li N, Kaur S, Greshock J, Lassus H, Zhong X, Wang Y, et al. A combined array-based comparative genomic hybridization and functional library screening approach identifies mir-30d as an oncomir in cancer. Cancer Res. 2012;72:154–64.PubMed CentralView ArticlePubMedGoogle Scholar
- Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 2008;299:425–36.PubMed CentralPubMedGoogle Scholar
- Kefas B, Godlewski J, Comeau L, Li Y, Abounader R, Hawkinson M, et al. microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res. 2008;68:3566–72.View ArticlePubMedGoogle Scholar
- Godlewski J, Nowicki MO, Bronisz A, Williams S, Otsuki A, Nuovo G, et al. Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioblastoma proliferation and self-renewal. Cancer Res. 2008;68:9125–30.View ArticlePubMedGoogle Scholar
- Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 2005;65:6029–33.View ArticlePubMedGoogle Scholar
- Miele E, Buttarelli FR, Arcella A, Begalli F, Garg N, Silvano M, et al. High-throughput microRNA profiling of pediatric high-grade glioblastomas. Neuro-Oncology. 2014;16:228–40.PubMed CentralView ArticlePubMedGoogle Scholar
- Yang L, Shi CM, Chen L, Pang LX, Xu GF, Gu N, et al. The biological effects of hsa-miR-1908 in human adipocytes. Mol Biol Rep. 2015;42:927–35.View ArticlePubMedGoogle Scholar
- Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene. 2005;24:7455–64.View ArticlePubMedGoogle Scholar
- Bellacosa A, Kumar CC, Di Cristofano A, Testa JR. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res. 2005;94:29–86.View ArticlePubMedGoogle Scholar
- Tsurutani J, Fukuoka J, Tsurutani H, Shih JH, Hewitt SM, Travis WD, et al. Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. J Clin Oncol. 2006;24:306–14.View ArticlePubMedGoogle Scholar
- Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res. 2003;9:2316–26.PubMedGoogle Scholar
- Lee HY, Moon H, Chun KH, Chang YS, Hassan K, Ji L, et al. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells. J Natl Cancer Inst. 2004;96:1536–48.View ArticlePubMedGoogle Scholar
- Potente M, Urbich C, Sasaki K, Hofmann WK, Heeschen C, Aicher A, et al. Involvement of Foxo transcription factors in angiogenesis and postnatal neovascularization. J Clin Invest. 2005;115:2382–92.PubMed CentralView ArticlePubMedGoogle Scholar
- Dansen TB, Burgering BM. Unravelling the tumor-suppressive functions of FOXO proteins. Trends Cell Biol. 2008;18:421–9.View ArticlePubMedGoogle Scholar
- Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol. 2004;24:200–16.PubMed CentralView ArticlePubMedGoogle Scholar
- Alao JP. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer. 2007;6:24.PubMed CentralView ArticlePubMedGoogle Scholar
- Land SC, Tee AR. Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J Biol Chem. 2007;282:20534–43.View ArticlePubMedGoogle Scholar
- Pisick E, Jagadeesh S, Salgia R. Receptor tyrosine kinases and inhibitors in lung cancer. Sci World J. 2004;4:589–604.View ArticleGoogle Scholar
- Blake Jr DC, Mikse OR, Freeman WM, Herzog CR. FOXO3a elicits a pro-apoptotic transcription program and cellular response to human lung carcinogen nicotine-derived nitrosaminoketone (NNK). Lung Cancer. 2010;67:37–47.View ArticlePubMedGoogle Scholar
- Ambros V. The functions of animal microRNAs. Nature. 2004;431:350–5.View ArticlePubMedGoogle Scholar
- Calin GA, Croce CM. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res. 2006;66:7390–4.View ArticlePubMedGoogle Scholar
- Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–69.View ArticlePubMedGoogle Scholar
- Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275:1943–7.View ArticlePubMedGoogle Scholar
- Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer. 2006;6:184–92.View ArticlePubMedGoogle Scholar
- Wang Y, Wang X, Zhang J, Sun G, Luo H, Kang C, et al. MicroRNAs involved in the EGFR/PTEN/AKT pathway in glioblastomas. J Neuro-Oncol. 2012;106:217–24.View ArticleGoogle Scholar
- Liliental J, Moon SY, Lesche R, Mamillapalli R, Li D, Zheng Y, et al. Genetic deletion of the Pten tumor suppressor gene promotes cell motility by activation of Rac1 and Cdc42 GTPases. Curr Biol. 2000;10:401–4.View ArticlePubMedGoogle Scholar
- Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science. 1998;280:1614–7.View ArticlePubMedGoogle Scholar
- Scagliotti GV, Selvaggi G, Novello S, Hirsch FR. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res. 2004;10:4227s–32.View ArticlePubMedGoogle Scholar
- Zhang J, Han L, Zhang A, Wang Y, Yue X, You Y, et al. AKT2 expression is associated with glioblastoma malignant progression and required for cell survival and invasion. Oncol Rep. 2010;24:65–72.PubMedGoogle Scholar
- Jiang H, Shang X, Wu H, Gautam SC, Al-Holou S, Li C, et al. Resveratrol downregulates PI3K/Akt/mTOR signaling pathways in human U251 glioblastoma cells. J Exp Ther Oncol. 2009;8:25–33.PubMed CentralPubMedGoogle Scholar
- Ruano Y, Mollejo M, Camacho FI, Rodriguez de Lope A, Fiano C, Ribalta T, et al. Identification of survival-related genes of the phosphatidylinositol 3’-kinase signaling pathway in glioblastoma multiforme. Cancer. 2008;112:1575–84.View ArticlePubMedGoogle Scholar
- Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst. 2001;93:1246–56.View ArticlePubMedGoogle Scholar
- Sasaki H, Zlatescu MC, Betensky RA, Ino Y, Cairncross JG, Louis DN. PTEN is a target of chromosome 10q loss in anaplastic oligodendroglioblastomas and PTEN alterations are associated with poor prognosis. Am J Pathol. 2001;159:359–67.PubMed CentralView ArticlePubMedGoogle Scholar
- Ermoian RP, Furniss CS, Lamborn KR, Basila D, Berger MS, Gottschalk AR, et al. Dysregulation of PTEN and protein kinase B is associated with glioblastoma histology and patient survival. Clin Cancer Res. 2002;8:1100–6.PubMedGoogle Scholar
- Raffel C, Frederick L, O’Fallon JR, Atherton-Skaff P, Perry A, Jenkins RB, et al. Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations. Clin Cancer Res. 1999;5:4085–90.PubMedGoogle Scholar
- Thorarinsdottir HK, Santi M, McCarter R, Rushing EJ, Cornelison R, Jales A, et al. Protein expression of platelet-derived growth factor receptor correlates with malignant histology and PTEN with survival in childhood glioblastomas. Clin Cancer Res. 2008;14:3386–94.PubMed CentralView ArticlePubMedGoogle Scholar
- Li Y, Guessous F, Johnson EB, Eberhart CG, Li XN, Shu Q, et al. Functional and molecular interactions between the HGF/c-Met pathway and c-Myc in large-cell medulloblastoma. Lab Investig. 2008;88:98–111.View ArticlePubMedGoogle Scholar
- Xia H, Ooi LL, Hui KM. MiR-214 targets beta-catenin pathway to suppress invasion, stem-like traits and recurrence of human hepatocellular carcinoma. PLoS ONE. 2012;7, e44206.PubMed CentralView ArticlePubMedGoogle Scholar